Isracann Biosciences Inc. (ISCNF)

Isracann Biosciences Cash Flow Statement

Financials in millions CAD. Fiscal year is June - May.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Aug 31, 2022	May 31, 2022	May 31, 2021	May 31, 2020	May 31, 2019
Net Income	-4.54	-4.69	-25.16	-24.2	-9.9
Depreciation & Amortization	0.04	0.04	0.04	0.05	0.04
Loss (Gain) From Sale of Assets	-	-	-0.25	-	-
Asset Writedown & Restructuring Costs	0.01	-	20.62	12.06	-
Loss (Gain) From Sale of Investments	1.35	1.35	-	-	-
Loss (Gain) on Equity Investments	0.13	0.13	-	-	-
Stock-Based Compensation	0.06	0.06	0.74	1.18	1.16
Other Operating Activities	-0.04	-0.09	-0.16	0.3	4.3
Change in Accounts Receivable	0.2	0.21	0.13	-0.06	-0.11
Change in Accounts Payable	0.56	0.44	-0.29	-0.08	0.06
Change in Other Net Operating Assets	0	0.04	0.1	0.25	0.12
Operating Cash Flow	-1.48	-1.75	-4.23	-10.4	-2.94
Capital Expenditures	-	-	-0.01	-	-0.2
Cash Acquisitions	0.04	0.04	-	0.03	-0.03
Divestitures	-	-	0.28	-	-
Sale (Purchase) of Intangibles	-	-	-	-0.51	-
Investment in Securities	-	-	-	-1.66	-
Other Investing Activities	-	-0.12	-0.14	-0.01	-0.62
Investing Cash Flow	0.04	-0.08	0.13	-2.63	-0.86
Issuance of Common Stock	0.28	0.13	2.18	13.29	10.15
Repurchase of Common Stock	-	-	-	-	-10.15
Other Financing Activities	-	-	-0.01	-0.53	-
Financing Cash Flow	0.28	0.13	2.17	12.76	-
Foreign Exchange Rate Adjustments	-0.05	-0.04	-0	-0.01	-
Net Cash Flow	-1.2	-1.74	-1.93	-0.29	-3.8
Free Cash Flow	-1.48	-1.75	-4.24	-10.4	-3.15
Free Cash Flow Per Share	-0.01	-0.01	-0.03	-0.11	-0.08
Levered Free Cash Flow	-0.57	-0.81	-2.29	4.06	-
Unlevered Free Cash Flow	-0.57	-0.81	-2.2	4.06	-
Change in Net Working Capital	-0.73	-0.61	-0.04	-10.36	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.